


STRAC Systems PI Committee Regional Clinical Practice Guidelines For the Rapid Treatment of Age ≥ 65 Head Injury Patients



Southwest Texas Regional Advisory Council



www.strac.org

V1_2019_05

MEDCOM 24/7 (210) 233-5815 medcom@strac.org

Guideline for Reversal of Oral Anticoagulants

Patients who arrive with significant hemorrhage (intra-cranial, intra-abdominal, intra-thoracic) or needs emergent operative intervention



Kcentra®=4-Factor PCC

If signs/symptoms of allergic reaction to infusion – stop infusion. Avoid Kcentra® in patients with history of HIT or allergy to albumin.

Praxbind®=Idarucizumab

Given as 2 consecutive 2.5 gram infusions. Praxbind contains 4 grams sorbitol. Consider this if calculating total daily amount of sorbitol/fructose in patients with hereditary fructose intolerance.

Original Prepared by: Rachel Garvin, M.D.,

Approved by the STRAC Executive Committee (05/2019) as modified from the UHS Anticoagulation Safety Committee.

Reference: 2012 ACCP Guidelines; Woo CH, et al. World Neurosurg 2014;81(1):110-15; Kuamatsu JB, et al. JAMA 2015;313(8):824-36;Idarucizumab (PRAXABIND®) package insert, Boehringer Ingelheim, December 2015. Frontera JA, et al. Neurocrit Care 2016;24:6-46.



Southwest Texas Regional Advisory Council
www.strac.org

V1_2019_05